25
Participants
Start Date
May 10, 2021
Primary Completion Date
December 1, 2024
Study Completion Date
December 1, 2024
TQB2450/Anlotinib hydrochloride/Oxaliplatin/Capecitabine
"Initial treatment (6 cycles):~1. TQB2450:1200 mg , Day 1 ivgtt ,once every 3 weeks~2. Anlotinib: 10 mg/day orally ,from days 1 to 14 in a 21-day cycle~3. Oxaliplatin: 130 mg / m2, Day 1 ivgtt ,once every 3 weeks~4. Capecitabine: 1000 mg / m2, orally, twice a day (once in the morning and once in the evening), from days 1 to 14 in a 21-day cycle Maintenance treatment:~1)TQB2450: 1200 mg , Day 1 ivgtt , once every 3 weeks 2)Anlotinib: 10 mg/day orally , from days 1 to 14 in a 21-day cycle"
Henan Cancer Hospital, Zhengzhou
Henan Cancer Hospital
OTHER_GOV